CAMBRIDGE, Mass. & LAFAYETTE, Colo.--(BUSINESS WIRE)--Jan. 5, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Dharmacon, Inc., a business unit of the Fisher Biosciences group and a leading supplier of innovative RNA and RNAi research products, announced today that Alnylam has granted Dharmacon a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned solely by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
